Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0VZXAQ
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
1131-MMAE
|
|||||
| Synonyms |
1131MMAE; 1131 MMAE
Click to Show/Hide
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 1 Indication(s)
Gastric cancer [ICD11:2B72]
Investigative
|
|||||
| Structure |
|
|||||
| Antibody Name |
C-1131
|
Antibody Info | ||||
| Antigen Name |
Kita-kyushu lung cancer antigen 1 (CT83)
|
Antigen Info | ||||
| Payload Name |
Monomethyl auristatin E
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Mc-Val-Cit-PABC
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
| Combination Type |
Vedotin
|
|||||
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
Revealed Based on the Cell Line Data
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 58.80% (Day 21) | Positive KKLC1 expression (KKLC1+++/++) | ||
| Method Description |
The inhibitory activity of 1131-MMAE against cancer cell growth was evaluated in various human cancer cell lines in vivo. The cells were treated with 0.3 mg/kg.
|
||||
| In Vivo Model | Gastric cancer CDX model | ||||
| In Vitro Model | Gastric adenocarcinoma | MKN45 cells | CVCL_0434 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 80.36% (Day 21) | Positive KKLC1 expression (KKLC1+++/++) | ||
| Method Description |
The inhibitory activity of 1131-MMAE against cancer cell growth was evaluated in various human cancer cell lines in vivo. The cells were treated with 1 mg/kg.
|
||||
| In Vivo Model | Gastric cancer CDX model | ||||
| In Vitro Model | Gastric adenocarcinoma | MKN45 cells | CVCL_0434 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 83.05% (Day 5) | Positive KKLC1 expression (KKLC1+++/++) | ||
| Method Description |
The inhibitory activity of 1131-MMAE against cancer cell growth was evaluated in various human cancer cell lines in vivo. The cells were treated with 3 mg/kg.
|
||||
| In Vivo Model | Gastric cancer CDX model | ||||
| In Vitro Model | Gastric adenocarcinoma | MKN45 cells | CVCL_0434 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 93.92% (Day 21) | Positive KKLC1 expression (KKLC1+++/++) | ||
| Method Description |
The inhibitory activity of 1131-MMAE against cancer cell growth was evaluated in various human cancer cell lines in vivo. The cells were treated with 2 mg/kg.
|
||||
| In Vivo Model | Gastric cancer CDX model | ||||
| In Vitro Model | Gastric adenocarcinoma | MKN45 cells | CVCL_0434 | ||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 3.87 nM | Positive KKLC1 expression (KKLC1+++/++) | ||
| Method Description |
The inhibitory activity of 1131-MMAE against cancer cell growth was evaluated in various human cancer cell lines in vitro.
|
||||
| In Vitro Model | Gastric signet ring cell adenocarcinoma | NUGC-4 cells | CVCL_3082 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 5.26 nM | Positive KKLC1 expression (KKLC1+++/++) | ||
| Method Description |
The inhibitory activity of 1131-MMAE against cancer cell growth was evaluated in various human cancer cell lines in vitro.
|
||||
| In Vitro Model | Gastric adenocarcinoma | MKN45 cells | CVCL_0434 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 786.00 nM | Positive KKLC1 expression (KKLC1+++/++) | ||
| Method Description |
The inhibitory activity of 1131-MMAE against cancer cell growth was evaluated in various human cancer cell lines in vitro.
|
||||
| In Vitro Model | Gastric carcinoma | HGC-27 cells | CVCL_1279 | ||
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.